Condensed Consolidated Statements of Changes in Equity (Statement) - USD ($) $ in Thousands		Total		Common Units		Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income	Retained Earnings	Noncontrolling Interests
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2022		$ 10,796
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to redeemable noncontrolling interests		(788)
Redeemable noncontrolling interests, ending balance at Mar. 31, 2023		10,008
Common units balance, beginning of period (in shares) at Dec. 31, 2022	[1]			482,726,544
Balance, beginning of period at Dec. 31, 2022		1,039,510		$ 510,968				$ 26,533	$ 101,549	$ 400,460
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Ardent Health Partners, Inc.		4,143							4,143
Net income attributable to noncontrolling interests		20,427								20,427
Other comprehensive income (loss)		(4,564)						(4,564)
Distributions to noncontrolling interests		(12,555)								(12,555)
Vesting of Class C Units (in shares)	[1]			587,053
Issuance of stock		360		$ 360
Common units balance, ending of period (in shares) at Mar. 31, 2023	[1]			483,313,597
Balance, ending of period at Mar. 31, 2023		1,047,321		$ 511,328				21,969	105,692	408,332
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2022		10,796
Redeemable noncontrolling interests, ending balance at Sep. 30, 2023		9,071
Common units balance, beginning of period (in shares) at Dec. 31, 2022	[1]			482,726,544
Balance, beginning of period at Dec. 31, 2022		1,039,510		$ 510,968				26,533	101,549	400,460
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Ardent Health Partners, Inc.		58,057
Other comprehensive income (loss)		56
Common units balance, ending of period (in shares) at Sep. 30, 2023	[1]			484,415,199
Balance, ending of period at Sep. 30, 2023		1,083,509		$ 496,701				26,589	159,606	400,613
Redeemable noncontrolling interests, beginning balance at Mar. 31, 2023		10,008
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to redeemable noncontrolling interests		(970)
Redeemable noncontrolling interests, ending balance at Jun. 30, 2023		9,038
Common units balance, beginning of period (in shares) at Mar. 31, 2023	[1]			483,313,597
Balance, beginning of period at Mar. 31, 2023		1,047,321		$ 511,328				21,969	105,692	408,332
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Ardent Health Partners, Inc.		33,076							33,076
Net income attributable to noncontrolling interests		23,600								23,600
Other comprehensive income (loss)		4,589						4,589
Distributions to noncontrolling interests		(19,254)								(19,254)
Redemption of equity attributable to noncontrolling interests		26,024		$ 14,990						11,034
Vesting of Class C Units (in shares)	[1]			558,013
Issuance of stock		182		$ 182
Common units balance, ending of period (in shares) at Jun. 30, 2023	[1]			483,871,610
Balance, ending of period at Jun. 30, 2023		1,063,490		$ 496,520				26,558	138,768	401,644
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to redeemable noncontrolling interests		33
Redeemable noncontrolling interests, ending balance at Sep. 30, 2023		9,071
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Ardent Health Partners, Inc.		20,838							20,838
Net income attributable to noncontrolling interests		17,837								17,837
Other comprehensive income (loss)		31						31
Distributions to noncontrolling interests		(18,868)								(18,868)
Vesting of Class C Units (in shares)	[1]			543,589
Issuance of stock		181		$ 181
Common units balance, ending of period (in shares) at Sep. 30, 2023	[1]			484,415,199
Balance, ending of period at Sep. 30, 2023		1,083,509		$ 496,701				26,589	159,606	400,613
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2023		7,302
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to redeemable noncontrolling interests		(2,285)
Redeemable noncontrolling interests, ending balance at Mar. 31, 2024		$ 5,017
Common units balance, beginning of period (in shares) at Dec. 31, 2023		484,922,828
Balance, beginning of period at Dec. 31, 2023		$ 1,075,014	[2]	$ 496,882		$ 0	$ 0	18,561	155,453	404,118
Balance, beginning of period (in shares) at Dec. 31, 2023		0		484,922,828	[3]	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Ardent Health Partners, Inc.		$ 27,047							27,047
Net income attributable to noncontrolling interests		21,089								21,089
Other comprehensive income (loss)		703						703
Distributions to noncontrolling interests		(14,256)								(14,256)
Vesting of Class C Units (in shares)	[3]			464,853
Issuance of stock		512		$ 512
Balance, ending of period at Mar. 31, 2024		1,110,109		$ 497,394		$ 0	0	19,264	182,500	410,951
Balance, ending of period (in shares) at Mar. 31, 2024				485,387,681	[3]	0
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2023		7,302
Redeemable noncontrolling interests, ending balance at Sep. 30, 2024		$ 2,391
Common units balance, beginning of period (in shares) at Dec. 31, 2023		484,922,828
Balance, beginning of period at Dec. 31, 2023		$ 1,075,014	[2]	$ 496,882		$ 0	0	18,561	155,453	404,118
Balance, beginning of period (in shares) at Dec. 31, 2023		0		484,922,828	[3]	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Ardent Health Partners, Inc.		$ 96,139
Other comprehensive income (loss)		$ (9,075)
Common units balance, ending of period (in shares) at Sep. 30, 2024		0
Balance, ending of period at Sep. 30, 2024		$ 1,384,478	[2]	$ 0		$ 1,428	743,364	9,486	251,592	378,608
Balance, ending of period (in shares) at Sep. 30, 2024		0		0	[3]	142,735,842
Redeemable noncontrolling interests, beginning balance at Mar. 31, 2024		$ 5,017
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to redeemable noncontrolling interests		(1,349)
Redeemable noncontrolling interests, ending balance at Jun. 30, 2024		3,668
Balance, beginning of period at Mar. 31, 2024		1,110,109		$ 497,394		$ 0	0	19,264	182,500	410,951
Balance, beginning of period (in shares) at Mar. 31, 2024				485,387,681	[3]	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Ardent Health Partners, Inc.		42,770							42,770
Net income attributable to noncontrolling interests		25,540								25,540
Other comprehensive income (loss)		(2,255)						(2,255)
Distributions to noncontrolling interests		(17,401)								(17,401)
Vesting of Class C Units (in shares)	[3]			522,002
Issuance of stock		226		$ 226
Balance, ending of period at Jun. 30, 2024		1,158,989		$ 497,620		$ 0	0	17,009	225,270	419,090
Balance, ending of period (in shares) at Jun. 30, 2024				485,909,683	[3]	0
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to redeemable noncontrolling interests		(1,277)
Redeemable noncontrolling interests, ending balance at Sep. 30, 2024		2,391
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Ardent Health Partners, Inc.		26,322							26,322
Net income attributable to noncontrolling interests		20,960								20,960
Other comprehensive income (loss)		(7,523)						(7,523)
Distributions to noncontrolling interests		(21,481)								(21,481)
Vesting of Class C Units (in shares)						13,800,000
Issuance of stock		199,122				$ 138	198,984
Conversion of member units to common stock (in shares)				(485,909,683)	[3]	(128,963,328)
Conversion of member units to common stock		0		$ (497,620)		$ 1,290	536,291			(39,961)
Vesting of restricted stock unit awards (in shares)						9,441
Tax withholding on vesting of restricted stock unit awards (in shares)						(2,396)
Tax withholding on vesting of restricted stock unit awards		(46)					(46)
Forfeiture of restricted stock awards (in shares)						(34,531)
Equity-based compensation		$ 8,135					8,135
Common units balance, ending of period (in shares) at Sep. 30, 2024		0
Balance, ending of period at Sep. 30, 2024		$ 1,384,478	[2]	$ 0		$ 1,428	$ 743,364	$ 9,486	$ 251,592	$ 378,608
Balance, ending of period (in shares) at Sep. 30, 2024		0		0	[3]	142,735,842

[1] (*) See Note 1, Description of the Business and Basis of Presentation - Initial Public Offering and Corporate Conversion, for further discussion.

[2] As of September 30, 2024 and December 31, 2023, the unaudited condensed consolidated balance sheets included total liabilities of consolidated variable interest entities of $303.2 million and $337.8 million, respectively. Refer to Note 2, Summary of Significant Accounting Policies, for further discussion.

[3] (*) See Note 1, Description of the Business and Basis of Presentation - Initial Public Offering and Corporate Conversion, for further discussion.